The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis
- PMID: 24642726
- DOI: 10.1159/000357780
The biological functions, structure and sources of CXCL10 and its outstanding part in the pathophysiology of multiple sclerosis
Abstract
The etiology of several autoimmune diseases, including multiple sclerosis (MS), has still not been completely clarified. MS is defined as an autoimmune disease with clinical features of a chronic, inflammatory and demyelinating autoimmune disorder which affects the central nervous system. The course of the disease includes phases of remission and relapses which can be exacerbated in both severity and duration. Chemokines, which are a subfamily of the cytokines, act as chemoattractants for a wide variety of cells, including immune cells. CXCL10 is a small protein that is defined as an 'inflammatory' chemokine and binds to CXCR3 to mediate immune responses through the activation and recruitment of leukocytes such as T cells, eosinophils, monocytes and NK cells. The aim of this review is to address recent findings regarding the relationship between CXCL10 and MS.
Similar articles
-
New insights into the role of stromal cell-derived factor 1 (SDF-1/CXCL12) in the pathophysiology of multiple sclerosis.J Neuroimmunol. 2016 Jan 15;290:70-5. doi: 10.1016/j.jneuroim.2015.11.021. Epub 2015 Nov 24. J Neuroimmunol. 2016. PMID: 26711573 Review.
-
CXCL10 and autoimmune diseases.Autoimmun Rev. 2009 Mar;8(5):379-83. doi: 10.1016/j.autrev.2008.12.002. Epub 2008 Dec 25. Autoimmun Rev. 2009. PMID: 19105984 Review.
-
Chemokines and chemokine receptors in multiple sclerosis. Potential targets for new therapies.Acta Neurol Scand. 2007 Mar;115(3):137-46. doi: 10.1111/j.1600-0404.2006.00749.x. Acta Neurol Scand. 2007. PMID: 17295707 Review.
-
Generation and Characterization of a Functional Nanobody Against Inflammatory Chemokine CXCL10, as a Novel Strategy for the Treatment of Multiple Sclerosis.CNS Neurol Disord Drug Targets. 2019;18(2):141-148. doi: 10.2174/1871527317666181114134518. CNS Neurol Disord Drug Targets. 2019. PMID: 30426906
-
[Recent prognosis on etiology and pathophysiology of multiple sclerosis].Nihon Rinsho. 2013 May;71(5):807-10. Nihon Rinsho. 2013. PMID: 23777086 Review. Japanese.
Cited by
-
Safety, tolerability, pharmacokinetics, and pharmacodynamics of a TLR7 agonist prodrug RO6870868 in healthy volunteers.Clin Transl Sci. 2021 Jul;14(4):1524-1534. doi: 10.1111/cts.13016. Epub 2021 Apr 9. Clin Transl Sci. 2021. PMID: 33742764 Free PMC article. Clinical Trial.
-
Botanically-Derived Δ9-Tetrahydrocannabinol and Cannabidiol, and Their 1:1 Combination, Modulate Toll-like Receptor 3 and 4 Signalling in Immune Cells from People with Multiple Sclerosis.Molecules. 2022 Mar 8;27(6):1763. doi: 10.3390/molecules27061763. Molecules. 2022. PMID: 35335126 Free PMC article.
-
Human polyomavirus BKV infection of endothelial cells results in interferon pathway induction and persistence.PLoS Pathog. 2019 Jan 8;15(1):e1007505. doi: 10.1371/journal.ppat.1007505. eCollection 2019 Jan. PLoS Pathog. 2019. PMID: 30620752 Free PMC article.
-
The Role of Chemokines in the Pathogenesis of HTLV-1.Front Microbiol. 2020 Mar 13;11:421. doi: 10.3389/fmicb.2020.00421. eCollection 2020. Front Microbiol. 2020. PMID: 32231656 Free PMC article. Review.
-
Investigating the Causal Effect of Brain Expression of CCL2, NFKB1, MAPK14, TNFRSF1A, CXCL10 Genes on Multiple Sclerosis: A Two-Sample Mendelian Randomization Approach.Front Bioeng Biotechnol. 2020 May 5;8:397. doi: 10.3389/fbioe.2020.00397. eCollection 2020. Front Bioeng Biotechnol. 2020. PMID: 32432099 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical